Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report.
Can J Anaesth · 2023
Last updated 2026-05-28A patient taking semaglutide for weight loss experienced regurgitation of stomach contents during anesthesia, even after fasting for 20 hours for solids and 8 hours for clear liquids. The medication, which slows digestion, was last taken two days before the procedure. The report suggests that long-acting GLP-1 drugs like semaglutide may increase the risk of stomach contents entering the lungs under anesthesia and recommends stopping the medication four weeks before surgery if possible.
AI summary of the abstract below.
| Journal | Can J Anaesth, 2023 |
|---|---|
| Citations | 104 |
| Relative citation ratio | 16.45 |
| NIH percentile | 99 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Abstract
PURPOSE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide are a class of medications prescribed to treat type 2 diabetes mellitus, and more recently, as an adjunct for weight loss because of its effects of delaying gastric emptying and suppressing appetite. Semaglutide is a long-acting agent with a half-life of approximately one week, and there are currently no guidelines that address the perioperative management of such agents.
CLINICAL FEATURES: We describe an unexpected case of regurgitation of a large volume of gastric contents upon induction of general anesthesia in a nondiabetic, nonobese patient despite a long preoperative fasting period (20 hr for solids and eight hours for clear fluids). This patient had no traditional risk factors for regurgitation or aspiration but was taking the GLP-1 RA semaglutide for weight loss and had last taken the medication two days before their scheduled procedure.
CONCLUSIONS: Patients taking long-acting GLP-1 RAs such as semaglutide may be at risk of pulmonary aspiration under anesthesia. We propose strategies to mitigate this risk including holding the medication four weeks prior to a scheduled procedure when feasible and considering full stomach precautions.
Verbatim abstract via PubMed 37280458 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.